Beta-Hairpin Peptidomimetics Stabilization for Selective Anti-Infective Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides, such as β-hairpin and β-sheet peptides, face challenges in achieving high potency and selectivity against pathogens like Bacillus subtilis and Shigella boydii, and existing antiviral agents do not effectively inhibit viral replication at different stages.
Innovation Solution
Development of β-hairpin peptidomimetics with specific amino acid sequences that stabilize β-hairpin conformations, allowing for selective anti-infective activity by restraining the peptide loop backbone into a hairpin geometry, using a template to enhance potency and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimicrobial peptides (β-hairpin and β-sheet peptides) are used, then anti-infective activity is achieved, but potency and selectivity against pathogens like Bacillus subtilis and Shigella boydii are insufficient
Solution Approach 1:
The patent modifies the peptide structure by changing parameters such as amino acid sequence, cyclization pattern, and conformational constraints to achieve enhanced potency and selectivity. Specifically, the invention uses template-directed synthesis to create β-hairpin peptidomimetics with precise structural parameters that optimize pathogen targeting while reducing off-target effects.
Solution Approach 2:
The patent creates composite peptidomimetic structures combining multiple functional elements within a single molecule. The β-hairpin peptidomimetics integrate cationic residues for membrane interaction, cyclized segments for structural stability, and specific amino acid sequences for pathogen selectivity, forming a composite structure that achieves both high potency and selectivity.
2Reliability
If antiviral agents are used to inhibit viral replication, then viral development is blocked, but effectiveness at different stages of replication is insufficient
Solution Approach 1:
The patent designs β-hairpin peptidomimetics with universal structural features that enable them to interact with multiple viral components across different replication stages. The conserved β-hairpin conformation and cationic character allow the peptides to target various viral membranes and proteins, providing multi-stage antiviral activity rather than stage-specific action.
3Reliability
If peptidomimetics are designed to stabilize β-hairpin conformations, then anti-infective activity is enhanced, but hemolysis of red blood cells increases
Solution Approach 1:
The patent applies local quality modification by introducing specific amino acid residues at particular positions within the peptide sequence. Certain residues are selected to enhance β-hairpin stability and pathogen targeting, while others are incorporated to reduce membrane damage. This localized optimization of specific regions allows the peptide to maintain high anti-infective activity while minimizing hemolytic effects.
Solution Approach 2:
The patent carefully adjusts structural parameters including the cyclization pattern, amino acid composition, and conformational constraints to optimize the balance between activity and toxicity. By modifying these parameters, the peptidomimetics achieve enhanced anti-infective activity while reducing harmful effects such as hemolysis.
4Reliability
If peptidomimetics are designed to stabilize β-hairpin conformations, then anti-infective activity is enhanced, but cytotoxicity increases
Solution Approach 1:
The patent uses local quality optimization by strategically placing specific amino acid residues that enhance β-hairpin stability and pathogen targeting capability while simultaneously reducing cytotoxicity. This localized modification allows the peptide to maintain high anti-infective activity against pathogens while minimizing damage to host cells.
Data Source
AI summary
β-Hairpin peptidomimetics of the general formula Cyclo(-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-), enantiomers and pharmaceutically acceptable salts thereof, with Xaa1-Xaa14 being amino acid residues of certain types which are defined in the description and the claims, have anti-infective activity, e.g. to selectively inhibit the growth of or to kill microorganisms such as Bacillus subtilis and/or Shigella boydii. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.